PeptidePedia The community reference

Contributions of IncretinIvo

User contributions·42 logged edits·page 1 of 1

Contributions by IncretinIvo, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 15,723 edits includes activity predating the current log.

  1. 03:14, 28 May 2026 (diff | hist) Chinese Peptide Company 15,513 ±0 convert the product range to a table so the documentation column lines up
  2. 10:58, 25 May 2026 (diff | hist) Active pharmaceutical ingredient 4,569 ±0 m add the effective date to the regulatory table
  3. 10:07, 25 May 2026 (diff | hist) Solid-phase peptide synthesis 5,359 ±0 m give the vial sizes in millilitres of nominal capacity
  4. 13:45, 3 Apr 2026 (diff | hist) Talk:Dual incretin agonist 611 +217 /* The GIP agonist-versus-antagonist problem */ reply
  5. 05:39, 17 Mar 2026 (diff | hist) Arcuate nucleus 5,251 ±0 m add the citation for the co-secretion finding
  6. 03:39, 6 Mar 2026 (diff | hist) Sterility testing 4,776 ±0 add the counterion determination method by name
  7. 17:27, 5 Mar 2026 (diff | hist) Test report forgery 5,391 ±0 m clarify that a signature on a certificate is a release, not a verification
  8. 19:49, 26 Feb 2026 (diff | hist) Bacterial endotoxin test 5,317 ±0 m add the reference standard and its traceability
  9. 15:30, 17 Feb 2026 (diff | hist) Talk:Survodutide 885 +108 /* Oxyntomodulin as template */ reply
  10. 13:20, 11 Feb 2026 (diff | hist) Talk:Timeline of incretin therapeutics 611 +79 /* The 1986 hinge */ reply
  11. 12:47, 9 Jan 2026 (diff | hist) Talk:Glucagon 885 +162 /* GIP and glucagon secretion — contradiction with the GIP article? */ reply
  12. 00:50, 15 Dec 2025 (diff | hist) Cost per milligram 4,125 ±0 m expand §Other axes that a price hides
  13. 16:30, 20 Oct 2025 (diff | hist) Zhuhai Kerui Biotechnology 9,552 +916 correct the trading name — the short code and the legal name are different things
  14. 01:02, 4 Oct 2025 (diff | hist) Qingdao Saber Technology Pharmaceutical 7,658 +109 state the city and province of the registered address
  15. 03:18, 17 Sep 2025 (diff | hist) Beta cell function 6,096 ±0 clarify that the receptor is expressed outside the pancreas
  16. 23:29, 6 Sep 2025 (diff | hist) Insulin secretion 6,940 ±0 m state that the enzyme inhibitor class works by raising endogenous levels
  17. 22:20, 25 Aug 2025 (diff | hist) Crude peptide 4,546 ±0 clarify that "cold chain" without a logger is a claim, not a record
  18. 02:08, 23 Aug 2025 (diff | hist) Contraindications of incretin therapy 4,842 ±0 add the citation for the gallbladder finding
  19. 00:31, 25 Jul 2025 (diff | hist) SURPASS trial programme 5,078 ±0 split overlong sentence
  20. 15:17, 11 Jul 2025 (diff | hist) Enteroendocrine L cell 5,083 ±0 m typo
  21. 05:41, 28 Jun 2025 (diff | hist) Third-party testing 6,906 ±0 m add the note on how to request a batch record rather than a certificate
  22. 13:08, 18 Jun 2025 (diff | hist) Xi'an Mokemei Biotechnology 7,057 +732 serial comma per PP:MOS
  23. 09:09, 22 May 2025 (diff | hist) Shanghai Wibson Biotechnology 7,557 ±0 m add the standing talk-page note link to the banner
  24. 18:25, 3 May 2025 (diff | hist) Exenatide 4,449 ±0 correct the molar mass — source gives the free-base figure, we had the salt
  25. 13:23, 1 Mar 2025 (diff | hist) ChinaPeptides 7,013 +144 m correct the trading name — the short code and the legal name are different things
  26. 20:18, 10 Feb 2025 (diff | hist) High-performance liquid chromatography 5,364 ±0 m add the plate-count expression and define its terms
  27. 13:40, 8 Feb 2025 (diff | hist) Crude peptide 3,651 +333 add the data-logger point: an unlogged shipment has no excursion record
  28. 03:01, 7 Feb 2025 (diff | hist) Incretin effect 5,425 +28 expand §Mechanisms: GLP-1 and GIP
  29. 13:24, 10 Jan 2025 (diff | hist) Glucose-dependent insulinotropic polypeptide 6,231 ±0 m correct the direction of the effect on gastric emptying
  30. 19:12, 9 Jan 2025 (diff | hist) Residual solvent 3,607 +727 m add the plate-count expression and define its terms
  31. 11:02, 9 Jan 2025 (diff | hist) Enteroendocrine L cell 4,107 +641 m expand §GLP-1 synthesis and secretion
  32. 17:27, 1 Jan 2025 (diff | hist) Contract development and manufacturing organisation 2,846 ±0 m expand §What a CDMO does
  33. 07:03, 30 Nov 2024 (diff | hist) Dual incretin agonist 4,447 +982 add the molecular formula to the infobox
  34. 12:26, 15 Nov 2024 (diff | hist) Proglucagon 3,465 +27 m close an unbalanced quotation mark
  35. 09:00, 6 Nov 2024 (diff | hist) Survodutide 1,456 +1,456 N create article — compound stub
  36. 22:48, 30 Oct 2024 (diff | hist) Hunan Aslsen Technology 4,271 +959 expand the product-scope row in the infobox
  37. 15:40, 28 Oct 2024 (diff | hist) Karl Fischer titration 4,966 +155 m convert a hard-coded date to the house format
  38. 23:14, 12 Oct 2024 (diff | hist) Lot traceability 2,794 +126 state the method the reporting service uses, since it is not the only one available
  39. 03:46, 6 Sep 2024 (diff | hist) Insulin syringe 2,620 +280 add the preservative point: unpreserved diluent changes the interval
  40. 13:40, 3 Sep 2024 (diff | hist) Talk:Glucagon-like peptide-1 611 +184 /* Residue numbering — (7–36) versus (1–30) */ reply
  41. 00:18, 29 Aug 2024 (diff | hist) Retatrutide 3,312 +106 attribute the mechanism claim to the review rather than stating it flatly
  42. 00:16, 6 Aug 2024 (diff | hist) Peptide synthesis 2,758 +411 state the difference between a validated shipper and an insulated box